Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317300 | 0.88 | PTGDR2 (0.41) | SIGMAR1PTGDR2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6319241 | 0.78 | HPGD (0.40) | MEN1KMT2AALDH1A1SIGMAR1TACR1 | |
| SCHEMBL6311513 | 0.75 | KDM4E (0.41) | SIGMAR1TACR1 | |
| SCHEMBL5745280 | 0.73 | TACR1 (0.37) | TACR1 | |
| SCHEMBL5746448 | 0.71 | DRD2 (0.44) | MEN1KMT2AALDH1A1SIGMAR1ACHE | |
| SCHEMBL5747642 | 0.69 | HSD11B1 (0.44) | MEN1KMT2AALDH1A1SIGMAR1ACHE | |
| SCHEMBL5746790 | 0.69 | PTGDR2 (0.41) | SIGMAR1PTGDR2 | |
| SCHEMBL6316979 | 0.66 | HTR2C (0.43) | MEN1KMT2ALMNACACNA1GCACNA1H | |
| SCHEMBL5744473 | 0.65 | DRD2 (0.40) | MEN1KMT2AALDH1A1LMNASIGMAR1 | |
| SCHEMBL6311280 | 0.65 | DRD2 (0.40) | MEN1KMT2ASIGMAR1CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | MEN1 861/4885KMT2A 944/4885ATM 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.